Our vision

Why was LAB591 created?

There is currently a lack of funding to help translate basic research in disease-related biological pathways into focused drug discovery program. LAB591 seeks to address this unmet need, to stimulate the formation of new companies to develop ground-breaking therapies, and ultimately to generate patient benefit.

Our partners

LAB591 is under the day-to-day administration of Fred Hutch, Evotec AG, and Arix Bioscience plc. All successful projects are selected by the joint steering committee before being admitted into the program.

"Through this very fast and efficient process, we can address important issues in healthcare and bridge the funding gap from research to commercialization.”

Hilary Hehman, MS, JD
Director of Partnerships and Alliances, Fred Hutch

Our mission

Our mission is three-pronged: To develop and identify commercializable assets based on disease-related novel biological pathways; to significantly shorten the drug discovery timeline and; to generate viable start-up companies with high potential for success.


The steering committee is composed of representatives from Fred Hutch, Evotec and Arix Bioscience.


Initial applications may be for Small Scale Awards (up to $50K to achieve basic proof of concept) or for Large Scale Awards (up to $250K and in exceptional cases, higher amounts).


LAB591 welcomes ad hoc applications, as well as applications in response to specific requests for proposals.


Applicants will benefit from financial support, technical expertise, and physical resources of LAB591 partners.

Meet Our Team

LAB591 is under the day-to-day administration of Fred Hutch, Evotec and Arix Bioscience. All successful projects are selected by the joint steering committee before being admitted into the program.

Stephanie Oestreich

Executive Vice President, Head BRIDGEs Partnerships North America, Evotec

Stephanie Oestreich conducted the research for her PhD in biochemistry at Harvard Medical School and obtained an MPA from the Harvard Kennedy School. She started in Strategic Alliances at Novartis in the US before moving to Basel to work for the CEO and taking on local, regional and global marketing roles in different geographies and therapeutic areas. She then worked for F. Roche Hoffmann-La Roche Ltd. as International Business Leader Avastin Breast, Cervical and Ovarian Cancer. Since 2017, she is Executive Vice President at Evotec and leads the North American BRIDGEs Partnerships.
From 2015 to 2017, she worked for F. Hoffmann La Roche as International Business Leader Avastin Breast, Cervical and Ovarian Cancer, and since September 2017 she is back in Boston as Executive Vice President, Head BRIDGEs Partnerships North America for Evotec, building alliances with academics, biotechnology, pharma and financing partners.

Daniel O'Connell

Investment Director, Arix Bioscience

Daniel has over 10 years’ of experience in healthcare. Daniel joined Arix Bioscience from OrbiMed Advisors, where he played key roles across investments in both biotherapeutics and medical devices. Investments he has supported include CardiAQ (acquired by Edwards), Civitas Therapeutics (acquired by Acorda), Relypsa (acquired by Galenica), Cynapsus (acquired by Sunovion), as well as other public and private companies. Prior to OrbiMed, Daniel was the Associate Director of Cardiovascular Research at Arisaph Pharmaceuticals where he was responsible for pre-IND discovery and development for programs in lipid modulation. He received his MD and PhD in Biochemistry from Tufts University School of Medicine, and has undergraduate degrees in Mathematics and Chemistry from MIT.

Iva Toudjarska

Senior Vice President, BRIDGEs Partnerships North America & NewCos, Evotec US, Inc.

Iva Toudjarska is part of the Evotec BRIDGEs North America team, including LAB591. Prior to joining Evotec, Iva spent 6 years in Biopharma strategy consulting enabling clients to develop strategic insights and decisions pertaining to new product development, portfolio prioritization, clinical development, commercial opportunity assessments, as well as due diligence for buy-side and sell-side opportunities. Previously, she was a founding employee at Alnylam Pharmaceuticals, the leader in RNAi therapeutics. During her 9 year tenure at Alnylam, as part of a multi-disciplinary team she advanced several programs to clinic, most notably ALN-RSV (a virology program) and ALN-VSP (an oncology program). She led the initiation of two hematology programs ALN-AT3 for the treatment of hemophilia (currently in clinic) and ALN-TMP for the treatment of beta-thalassemia.

Iva earned a Doctor of Philosophy from Bulgarian Academy of Sciences in Molecular Genetics and Masters of Business Administration from F.W. Olin Graduate School of Business at Babson College.

Jonathon Peacock

Executive Chairman, Arix Bioscience

Jonathan Peacock is the Executive Chairman of Arix Bioscience, Chairman of Bellerophon Therapeutics and a Board Member of Avantor Inc. From 2014 - 2017 he was also a Board member of Kite Pharma. Jon was formerly CFO of Amgen Inc. based in California and prior to that CFO of the Pharmaceuticals Division of Novartis AG, based in Switzerland. Before joining the pharma industry, Jon was a partner at McKinsey and Co, where he was co-head of the European Corporate Finance practice, and was also a partner at Price Waterhouse in London and New York. He is a graduate of the University of St Andrews in Scotland.